Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to update our to-do list, schedule online calls, and sort out deadlines. To cope, we are quaffing several cups of stimulation, of course. Our choice today is maple bourbon. Meanwhile, here is the latest selection of interesting items for you to peruse. We hope your day is successful and productive. And please do keep in touch. …
European regulators detailed their demands that Illumina divest the cancer diagnostics firm Grail, the latest fallout from the sequencing giant’s troubled 2021 acquisition, STAT writes. The move was just the most recent regulatory action against the deal. The European Commission in September 2022 ruled that the purchase violated antitrust rules, and the new order spelled out how the commission thought the deal should be unraveled. In July the commission also fined Illumina $460 million…
Click here to view original post
